BuyandBill.com

Announcing the BuyandBill.com Retina Report! 4th edition, Q2 2025 View Here: https://lnkd.in/eTBVb4zU We’re excited to announce that the BuyandBill.com Retina Report is now available! As part of our commitment to delivering valuable insights to healthcare providers, we’re offering this report free of charge for a limited time. The BuyandBill.com Retina Report will be published quarterly and provide an overview of pricing trends and pipeline information for ophthalmology drugs. Our focus is on drugs that treat wet age-related macular degeneration and geographic atrophy as well as intraocular steroids and other ophthalmology products. A high degree of importance is placed on the aflibercept and ranibizumab biosimilar classes. The Retina Report will provide readers with an understanding of: ASP quarterly monitoring and its importance Tracking drug discounting through analysis of ASP/WAC ratios Future medications: understanding the development pipeline To access the report at no charge, click the link below:?https://lnkd.in/eTBVb4zU

April 2025 ASP Pricing Available at?Pricing.BuyandBill.com! The preliminary April 2025 ASP file was published by the Centers for Medicare and Medicaid Services (CMS) on March 11th. Updated average sales price information is published every quarter by the Centers for Medicare and Medicaid Services (CMS). ASP is used as the primary reimbursement benchmark by government payers, as well as many commercial plans. It is crucial for healthcare providers to monitor ASP closely as quarterly fluctuations will directly influence reimbursement. The below table shows some of the most prominent quarterly ASP changes from January to April. Please note that this list is not exhaustive, and only represents a small number of the averages sales price changes that occurred from quarter one to quarter two. *Please note that the ASP is not the same as the Medicare Payment Limit and numbers are based on a preliminary file, subject to change* Industry members should also note that several changes have been made to previous ASP files, specifically in the biosimilar space. The BuyandBill.com team is working to identify these changes and ensure our historical data is updated with the correct information from CMS.

Did you know that virtually all health plans now require NDC codes on all medical drug claims? Claims without NDC codes or with improper NDC to HCPCS alignments are the leading cause of administrative claims denials for your providers. We can help ensure a successful launch of your Buy and Bill brand. BuyandBill.com has helped launch over 150 new products over the past 10 years. Whether you are launching a new product or introducing a new package or formulation, BuyandBill.com can help ensure proper alignment across pricing compendia and payer claims systems. Our market proven program includes three key strategies: - Ensuring accurate product compendia listing (Red Book, Medi-Span, FDB, Gold Standard) - Raising Payer and Claims processor awareness of your new product info - Verifying claims system status of your new code and identifying potential errors proactively https://lnkd.in/eDHMxe-x

New HCPCS Approvals: Effective April 1st, 2025 BuyandBill.com publishes a general summary of the Centers for Medicare and Medicaid services (CMS) level II HCPCS coding decisions for the upcoming quarter. Level II HCPCS applications are submitted to CMS two quarters in advance. CMS Level II HCPCS Coding Decisions (Partial List) *This list is not exhaustive*

January 2025 ASP is Available on BuyandBill.com! Login and view pricing here: https://lnkd.in/e-XCg_xn See some of the biggest movers based on the preliminary ASP file below. *Note that listed average sales prices are subject to change*

HCPCS Approvals for January 1, 2025 The HCPCS approvals and modifications for Quarter 1, 2025 are now available on BuyandBill.com! Login to BuyandBill.com here: https://lnkd.in/d3fbBm4W to access the complete list. *The picture below is not exhaustive*

October 2024 ASP Pricing Online Now at?BuyandBill.com The preliminary October 2024 ASP file was published by the Centers for Medicare and Medicaid Services (CMS) on September 11th. Updated average sales price information is published every quarter by the Centers for Medicare and Medicaid Services (CMS). ASP is used as the primary reimbursement benchmark by government payers, as well as many commercial plans. It is crucial for healthcare providers to monitor ASP closely as quarterly fluctuations will directly influence reimbursement. The below table shows some of the most prominent quarterly ASP changes from July to October. Please note that this list is not exhaustive, and only represents a small number of the averages sales price changes that occurred from quarter three to quarter four. *Please note that the ASP is not the same as the Medicare Payment Limit*

Check out the BuyandBill.com Comparative Pricing Report! Select a group of drugs or HCPCS codes of your choosing to easily compare and analyze pricing data at the HCPCS unit level. Users can graph ASP, WAC, and AWP data. https://lnkd.in/dgHsywMb

Check out the BuyandBill.com Comparative Pricing Report! Select a group of drugs or HCPCS codes of your choosing to easily compare and analyze pricing data at the HCPCS unit level. Users can graph ASP, WAC, and AWP data. https://lnkd.in/dgHsywMb

CMS HCPCS Coding Decisions: Effective October 1st, 2024 CMS has published a list of HCPCS coding decisions effective Quarter 4, 2024. There are several biosimilar Q codes as well as multiple 505(b)(2) pathway drugs. KISUNLA, also recieved a code that became effective immediately with drug approval, July 2nd, 2024.